BVI has earned U.S. Food and Drug Administration (FDA) approval for its FINEVISION HP trifocal intraocular lens (IOL), expanding advanced vision solutions for U.S. patients.

The work of BVI R&D Director Christophe Pagnoulle and ophthalmologist Damien Gatinel, M.D., Ph.D., brought the FINEVISION HP to market and heralded a new era of premium intraocular lenses (IOLs), according to the company. FINEVISION HP reportedly is the world’s first trifocal IOL and is touted as the global benchmark in trifocal innovation, boasting more than 15 years of clinical success and millions of implantations worldwide. The lens’ patented diffractive optic design delivers balanced vision at far, intermediate, and near distances.

“FINEVISION HP redefined premium cataract surgery and continues to set the gold standard in premium IOL innovation,” BVI President/CEO Shervin Korangy stated. “This FDA approval marks a pivotal step in expanding our IOL portfolio in the United States, supporting our mission to deliver best-in-class visual outcomes for patients globally.”

The third-generation FINEVISION HP incorporates BVI’s proprietary POD platform and CoPODize technology, harmonizing light distribution and minimizing visual disturbances. Its double C-loop, four-point haptic design supports long-term stability and precise centration in the capsular bag.

“The development of FINEVISION HP was a pivotal moment for ophthalmology, reshaping expectations for vision correction after cataract surgery,” Dr. Gatinel said. “FDA approval in the U.S. means even more patients will benefit from this breakthrough technology.”

FINEVISION HP was considered a breakthrough diffractive design that created the world’s first trifocal IOL, establishing a new standard in cataract surgery. With more than a decade of real-world clinical results, millions of successful implantations and strong surgeon preference, FINEVISION HP is a trusted trifocal lens, BVI bigwigs claim.

Featuring BVI’s proprietary POD platform, FINEVISION HP uses CoPODize technology to harmonize light distribution and minimize visual disturbances, while its double C-loop haptic system ensures lasting stability and precise centration.

Building on this global foundation of success, a U.S. clinical study has further demonstrated the lens’s potential impact for U.S. patients. “The FINEVISION HP trifocal IOL reflects innovation in optic design, and I’m pleased to have been part of the U.S. study evaluating its performance. This lens represents an important step forward in expanding advanced IOL choices for surgeons and their patients,” said Vance Thompson, M.D., an ophthalmologist and study investigator.

BVI will methodically roll out the FINEVISION HP trifocal IOL over the coming year.

BVI is a diversified global ophthalmic device company delivering solutions for advancing eye surgery and improving patients’ vision. With nine decades of developing products and solutions, BVI partners with ophthalmic surgeons to improve vision for millions of patients worldwide. The company supports surgical teams in more than 90 countries worldwide, either directly or through its distribution network.